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In acromegalic patients, cardiovascular and metabolic
comorbidities contribute to enhance mortality. Available data on the
lipoprotein profile of these patients are controversial. Our aim was
to characterize the lipoprotein profile and emergent biomarkers of
cardiovascular disease in active acromegalic patients in comparison









Glucose levels, hormonal status, lipoprotein profile
and C reactive protein (CRP) were evaluated by standardized methods.









) were measured by radiometric
techniques, endothelin-1 and vascular cell adhesion molecule
(VCAM)-1 by enzyme-linked immunosorbent assay, and leucocytes




After adjusting for body mass index (BMI), acromegalic
patients presented a more atherogenic lipoprotein profile, consisting
of higher levels of triglycerides and apolipoprotein B and alterations
in the ratios which estimate insulin resistance and atherogenic risk.
CETP activity was significantly increased in acromegalic patients as

































 < 0·01) and showed













 < 0·01 for all of them; with
BMI as a fixed variable). Lymphocytes from acromegalic patients





















Taken together, the alterations described seem to
contribute to constituting a state of higher propensity for the
development of atherosclerotic cardiovascular disease, which adds
to the presence of specific cardiomyopathy.
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In acromegalic patients, cardiovascular, respiratory and metabolic
comorbidities contribute to significantly enhance mortality, which
doubles the death rates in comparison with healthy population. In
fact, average life expectancy in patients with active acromegaly is




 Accordingly, the integrated
evaluation of the atherogenic risk, analysed through the Framingham
score, and the coronary artery calcium quantification has shown that
41% of acromegalic patients have an increased risk of coronary




The systemic complications observed in relation to acromegaly





harmful effect of GH and IGF-I excess on cardiac structure and












Nevertheless, the poor prognosis of acromegalic patients could be





to atherosclerotic cardiovascular disease. Actually, this high cardio-
vascular risk could be attributed to the increased incidence of diabetes
mellitus, hypertension and lipid disorders in acromegalic patients.
Although several studies agree on reporting the presence of an abnormal
lipid and lipoprotein profile in acromegalic patients, controversial
data arise when trying to identify the modified specific lipid parameters
or when analysing the extent of those alterations. Accordingly,









 and high density lipoprotein-cholesterol








Regarding emergent biomarkers of cardiovascular disease, most




 small and dense

















 showed reduced C reactive
protein (CRP) and unchanged homocysteine levels. To our knowledge,
no studies have been carried out to evaluate other atherogenic or









), endothelin-1, and soluble or leucocyte cell adhesion
molecules in acromegalic patients in comparison to healthy controls.
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The aim of the present study was to further characterize lipid,
lipoprotein and apolipoprotein profile, and emergent biomarkers of





cell adhesion molecule-1 (VCAM-1) and leucocyte CD18, CD49d







Eighteen adult patients with diagnosis of active acromegaly were
consecutively recruited from the Endocrinology Service,  ‘José de San
Martín’ Clinical Hospital, Buenos Aires, Argentina, during a period
of 1 year (Table 1). Patients were included in the present study when
presenting typical clinical features and increased GH and IGF-1




 Disease duration ranged
between 2 and 10 years. Three acromegalic patients had type 2
diabetes, seven had hypertension and 10 macroadenomas. Eighteen
healthy subjects, sex- and age-matched with the patients, agreed to
participate in this study and were employed as controls. Both
patients and controls had normal renal, hepatic and thyroid
functions, none of them presented history of any cardiovascular
event, and they were not under any treatment known to affect
carbohydrates, lipids or biomarkers of cardiovascular disease.
Informed consent was obtained from all participants and the
protocol of this open transversal study was approved by the Ethical
Committees from School of Pharmacy and Biochemistry and from
‘José de San Martín’ Clinical Hospital, University of Buenos Aires.
 
Study protocol and samples
 
After a 12-h overnight fast, venous blood was drawn from the














C. Serum was immediately employed for glucose determi-




C for lipid and lipoprotein characterization





nation of insulin, GH, IGF-I, IGFBP-3 and VCAM-1 levels, and for









C and employed for the evaluation





Glucose, triglycerides and total cholesterol were quantified by
standardized methods (Roche Diagnostics, Mannheim, Germany) in
a Hitachi 917 autoanalyser. Within-run precision (CV) was 1·3% and
1·1%, respectively, for triglycerides and total cholesterol. Between-day
precision (CV) was 2·4% and 1·5%, respectively. Laboratory bias was
1·1% and –1·7%, respectively. LDL-C level was determined as the
difference between total cholesterol and the cholesterol contained in
the supernatant obtained after selective precipitation of LDL with





 Within-run and between-day precisions (CV) were
4·7% and 5·0%, respectively. HDL was isolated in the supernatant
obtained following precipitation of apo B-containing lipoproteins





 Within-run and between-day precisions (CV) for HDL-C
were 3·2% and 3·8%, respectively. Laboratory bias was –2·0%.
VLDL-C was calculated as the difference between the cholesterol
contained in the supernatants obtained for LDL and HDL measure-
ments, while non-HDL-C was estimated as the difference between
total cholesterol and HDL-C. Apo B and apo A-I were evaluated by
immunoturbidimetry (Roche Diagnostics) in a Hitachi 917 autoanalyser.
Within-run and between-day precisions (CV) were 1·2% and 2·1%
for apo B, and 1·9% and 2·4% for apo A-I, respectively. The following
ratios were calculated: triglycerides : HDL-C, total cholesterol :
HDL-C, LDL-C : HDL-C and apo B : apo A-I. CRP concentration
was determined by Tina-quant CRP (Latex) high sensitive
immunoturbidimetric assay (Roche Diagnostics) in a Hitachi 917
autoanalyser. Within-run and between-day precisions (CV) were
0·4% and 3·4%, respectively. White blood cell count was determined




Insulin concentration was measured by microparticle enzyme
immunoassay (MEIA) (ABBOTT, Japan). Within-run and between-day
precisions (CV) were 2·9% and 4·4%, respectively. Homeostasis





U/ml)]/22·5. Serum GH was measured by the ultrasensitive
immunometric assay (Access®, Beckman Coulter™) with analytical




g/l. Within-run and between-day precisions
(CV) were 12·3% and 15·5%, respectively. Serum IGF-I and IGFBP-
3 levels were measured by Immulite 2000, solid phase chemi-
luminiscent enzyme immunoassay (Diagnostics Products Corp., Los
Angeles, CA) with analytical sensitivity of 2·6 nmol/l and 0·1 mg/l.
Within-run and between-day precisions (CV) for IGF-I were below
Table 1. Clinical characteristics, biomarkers of insulin resistance and 
hormonal parameters from acromegalic patients and control subjects
Acromegalic patients Control subjects
N  18  18
Women/Men  15/3  15/3
Age (years) 44 (27–79) 43 (28–76)
BMI (kg/m2) 28·0 (23·3–42·7) 23·4 (19·0–27·6)*
Waist (cm) 94 (77–112) 88 (70–99)
Glucose (mmol/l) 5·7 (4·2–17·7) 4·9 (4·0–5·5)**
Insulin (pmol/l) 121 (40–400) 37 (14–72)***
Glucose/Insulin 0·06 (0·03–0·11) 0·14 (0·08–0·40)***
HOMA 4·4 (1·1–44·1) 1·1 (0·5–2·2)***
GH (µg/l) 9·0 (2·2–308·0) 1·4 (0·2–9·3)*
IGF-1 (nmol/l) 90 (36–142) 19 (10–27)*
IGFBP-3 (mg/l) 7·6 (5·0–7·4) 4·5 (2·8–5·7)*
BMI, body mass index; HOMA, homeostasis model assessment; 
GH, growth hormone; IGF-1, insulin-like growth factor I; IGFBP-3, 
IGF binding protein-3. Results are expressed as median (range).
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5·4% and 11·9%, respectively. Measurements of IGFBP-3 were all





CETP activity was determined in serum samples following the




 with a few modifications.
Briefly, the ability of serum to promote the transfer of tritiated













) (NEN Life Science Products, Boston, MA) to













mol/l cholesterol) and 1·5 mmol/l




C. After incubation, lipoproteins were
separated by a selective precipitation method employing 40 g/l





was measured both in the incubation mixture and in the supernatant
containing the HDL fraction in a Liquid Scintillation Analyser
(Packard 210TR; Packard Instruments, Meridian, CT). Results were









 to apo B-containing lipoproteins, per millilitres per hour.
Measurements were all carried out in duplicate within the same










 activity was measured following the radiometric assay








 with a few modifications. The separation
of the released radiolabelled acetate from the lipid substrate was
carried out by phase–phase partitioning and measurement of the























in a total volume of 0·5 ml of phosphate-buffered saline (PBS)
(pH = 7·4). The tritiated substrate 1-hexadecyl-2-[3H] acetyl-glycero-
3-phosphocholine (13·5 Ci/mmol) was obtained from New England
Nucleotides and the nontritiated one was obtained from Cayman
Chemical. Once the substrates were mixed, the solvents were evaporated
under a stream of nitrogen and redissolved in PBS. There was a
sonication step consisting of one cycle of 5 min. Incubation was




C and the enzymatic reaction was
stopped by placing the tubes in an ice bath and by the addition of
1·5 ml of chloroform. Then, 0·5 ml of saturated sodium bicarbonate
solution was added. After centrifugation, the aqueous phase was
washed twice with 1·5 ml of chloroform. The radioactivity of the
aqueous phase of each sample and sample-blanks was measured by
liquid scintillation using a Packard autoanalyser. Radioactivity of the




mol/ml h. Measurements were all carried out within the same assay.




Endothelin-1 and VCAM-1 plasma levels were determined by the
monoclonal antibody-based enzyme-linked immunosorbent
assay (ELISA) following the manufacturer’s instructions, with a few
modifications (R&D Systems, USA). Sample levels were calculated by
analysing standards with known concentrations of recombinant





concentration. Within-run and between-day precisions (CV) were
4·5% and 5·5% for endothelin-1, and 3·5% and 7·7% for VCAM-1,
respectively.
 
Leucocyte cell adhesion molecules
 
Expression of the following adhesion molecules in monocytes,
polymorphonuclear cells, and lymphocytes was measured by flow





 Staining was performed in whole blood with
commercial fluorescein-isothiocyanate (FITC)-conjugated
anti-CD54 and anti-CD18, and phycoerythrin (PE)-conjugated
anti-CD49d monoclonal antibodies (MAbs, BD Biosciences
Pharmingen, Ontario, Canada). Whole blood was incubated with
saturating concentrations of conjugated MAbs for 30 min at room
temperature. Erythrocytes were lysed with commercially available
solution (FACS Lysing Solution, BD Biosciences Pharmingen). The
cells were then washed with PBS and immediately subjected to flow
cytometry equipped with a 488 nm argon laser. To analyse mono-
cytes, polymorphonuclear cells and lymphocytes, a gate was defined





 software (Becton-Dickinson). Moreover, monocyte
identity was confirmed by employing FITC or PE-conjugated anti
CD14. The fluorescence intensity of 10 000 events was recorded as
the mean channel number over a logarithmic scale of 1–1026
channels. Results were expressed as the mean channel of fluorescence
intensity. Fluorescent-conjugated isotype control antibodies were
used to detect nonspecific binding to cells.
 
Data and statistical analysis
 
Data distribution was tested employing the Shapiro-Wilk test.




 standard deviation (SD) for
normally distributed data and as median (range) for skewed data.
In this last case, data were normalized by log-transformation. Then,
analysis of covariance was used including body mass index (BMI)
as a covariate. Partial correlations were performed between different
parameters including BMI as a fixed variable. Differences were con-




 < 0·05 in the bilateral situation. For statistical




In the present study, 18 patients with active acromegaly were studied
in comparison with 18 sex- and age-well-matched control subjects.
Clinical characteristics, biomarkers of insulin resistance and hormonal
parameters are shown in Table 1. In accordance with the well-known
physical features of subjects with acromegaly, BMI was significantly
increased in the patients’ group. Given this difference between both
studied groups, all the results obtained were compared performing
analysis of covariance, including BMI as a covariate. Then, glucose
and insulin levels, as well as glucose : insulin ratio and HOMA were
higher in patients than in control individuals. Moreover, deriving
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from the inclusion criteria, GH, IGF-I and IGFBP-3 concentrations
were also elevated in patients with active acromegaly.
Table 2 shows lipid, lipoprotein and apolipoprotein levels.
Acromegalic patients presented a more atherogenic lipoprotein
profile than control subjects, consisting of higher triglyceride
(53%) and apo B (33%) levels. Ratios indicating insulin resistance
(TG : HDL-C) and atherogenic risk (TC : HDL-C, LDL-C : HDL-C
and apo B : apo A-I) were also higher in acromegalic patients.
Furthermore, CETP activity was found to be 19% higher in patients






















When analysing the association between hormones, which define
the acromegalic state, and different biochemical parameters evaluated
in the present study, significant correlations were observed between
GH, IGF-1 and/or IGFBP-3, and most indicators of insulin resistance
and lipid risk factors for atherosclerosis (Table 3).
Regarding inflammatory and atherogenic biomarkers, endothelin-1
levels evidenced a significant increase of 29% in the patients’ group.
Moreover, positive and significant correlations were observed

















 = 36). Besides,
endothelin-1 also showed positive associations with other biomarkers

















 < 0·05 for both of them). No





 activity and white blood cell count































Cell adhesion molecules were also evaluated in circulating leucocytes
and then, lymphocytes from acromegalic patients showed increased





In the present study, patients with active acromegaly, defined by
typical clinical features and increased GH and IGF-1 levels, showed
a more atherogenic lipid and lipoprotein profile than healthy control
subjects matched for sex and age and analysed fixing BMI as a
covariate. Moreover, among the different biomarkers of cardiovascular




, endothelin-1, VCAM-1, white
blood cell count and leucocyte cell adhesion molecules. Acromegaly
was associated with significantly higher levels of endothelin-1, the
most potent constrictor of human vessels known up to date, and with
an increased CD49d content in circulating lymphocytes, which are
Table 2. Lipids, lipoproteins and apolipoproteins from acromegalic patients 
and control subjects
Acromegalic 
patients (n = 18)
Control 
subjects (n = 18)
TG (mmol/l) 1·40 ± 0·43 0·91 ± 0·28*
TC (mmol/l) 5·50 ± 0·88 5·37 ± 1·03
VLDL-C (mmol/l) 0·59 ± 0·21 0·46 ± 0·18
LDL-C (mmol/l) 3·64 ± 0·75 3·20 ± 0·70
HDL-C (mmol/l) 1·27 ± 0·31 1·55 ± 0·39
Non-HDL-C (mmol/l) 4·23 ± 0·77 3·67 ± 0·80
Apo B (g/l) 1·09 ± 0·19 0·82 ± 0·18*
Apo A-I (g/l) 1·48 ± 0·29 1·52 ± 0·20
TG/HDL-C 2·7 ± 1·0 1·4 ± 0·4*
TC/HDL-C 4·5 ± 0·9 3·4 ± 0·6*
LDL-C/HDL-C 3·0 ± 0·8 2·2 ± 0·5*
APO B/APO A-I 0·8 ± 0·2 0·6 ± 0·1**
TG, triglycerides; TC, total cholesterol; VLDL, very low density lipoprotein; 
LDL, low density lipoprotein; HDL, high density lipoprotein; apo, 
apolipoprotein. Results are expressed as mean ± S.D.
*P < 0·005; **P < 0·01 vs. acromegalic patients.
Table 3. Correlations of GH, IGF-1 and IGFBP-3 with different parameters 







Glucose 0·48 (< 0·005) 0·40 (< 0·05) 0·49 (< 0·005)
Insulin 0·63 (< 0·0001) 0·74 (< 0·0001) 0·79 (< 0·0001)
Glucose/Insulin –0·51 (< 0·005) –0·70 (< 0·0001) –0·70 (< 0·0001)
HOMA 0·63 (< 0·0001) 0·68 (< 0·0001) 0·75 (< 0·0001)
TG 0·58 (< 0·0005) 0·53 (< 0·005) 0·64 (< 0·0001)
VLDL-C 0·52 (< 0·005) 0·35 (< 0·05) 0·51 (< 0·05)
LDL-C 0·29 (= 0·094) 0·20 (NS) 0·27 (NS)
HDL-C –0·04 (NS) –0·31 (= 0·078) –0·31 (= 0·078)
Non-HDL-C 0·40 (< 0·05) 0·25 (NS) 0·35 (< 0·05)
Apo B 0·37 (< 0·05) 0·37 (< 0·05) 0·35 (< 0·05)
Apo A-I 0·07 (NS) –0·17 (NS) –0·14 (NS)
TG/HDL-C 0·50 (< 0·005) 0·59 (< 0·0005) 0·68 (< 0·0001)
TC/HDL-C 0·38 (< 0·05) 0·50 (< 0·005) 0·59 (< 0·0005)
LDL-C/HDL-C 0·26 (NS) 0·43 (< 0·05) 0·49 (< 0·05)
APO B/APO A-I 0·40 (< 0·05) 0·41 (< 0·05) 0·39 (< 0·05)
CETP 0·20 (NS) 0·32 (= 0·066) 0·35 (< 0·05)
GH, growth hormone; IGF-1, insulin-like growth factor I; IGFBP-3, IGF 
binding protein-3; TG, triglycerides; VLDL, very low density lipoprotein; 
LDL, low density lipoprotein; HDL, high density lipoprotein; 
apo, apolipoprotein; CETP, cholesteryl ester transfer protein.
Table 4. Inflammatory and atherogenic markers from acromegalic patients 
and control subjects
Acromegalic 
patients (n = 18)
Control 
subjects (n = 18)
CRP (mg/l) 0·2 (0·1–22·7) 0·9 (0·1–13·7)
Lp-PLA2 (μmol/ml h) 8·1 ± 2·0 8·0 ± 1·7
Endothelin-1 (ng/l) 0·9 ± 0·2 0·7 ± 0·2*
VCAM-1 (μg/l)  41 ± 12  37 ± 7
White blood cell 
count (103/mm3)
6·1 ± 1·2 6·3 ± 1·8
CRP, C-reactive protein; VCAM-1, vascular cell adhesion molecule-1; 
Lp-PLA2, lipoprotein-associated phospholipase A2. Results are expressed as 
mean ± SD, except for CRP which is expressed as median (range).
*P < 0·01 vs. acromegalic patients.
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partially responsible for the inflammatory process linked to
atherosclerosis.
Evaluation of carbohydrate metabolism showed an increase in
insulin resistance, evidenced by alterations in glucose and insulin
plasma levels, glucose : insulin and HOMA ratios, as well as in
triglyceride : HDL-C ratio. The latter has been proposed as an
interesting marker to identify insulin-resistant individuals at high
risk of cardiovascular disease.21 Three of the acromegalic patients
studied in this work suffered from type 2 diabetes. When they were
discarded, no changes were detected in any of the evaluated parameters
(data not shown). It is worthy to note that insulin resistance is a very
common metabolic abnormality present in most, although not all,
patients with acromegaly.22,23 In the fasting state, acromegalic
patients show an impaired glucose utilization by adipose tissue, while
in the postprandial condition, this insulin resistance is further
amplified and antilipolysis also appears.23 An increased activity of
GH axis could amplify the insulin-resistant state. In fact, several
studies carried out in experimental animals have documented
numerous changes in the insulin signalling pathway that are induced
by GH excess.24
It is well-known that insulin resistance is responsible for different
disturbances in lipid and lipoprotein metabolism.25 In the present
study, acromegalic patients showed higher triglyceride levels
probably due to the accumulation of VLDL particles, and increased
apo B concentration. This reflects the presence of a more atherogenic
lipid and lipoprotein profile in acromegalic patients than in control
subjects, which is also confirmed by higher values observed in
different ratios evaluating atherosclerotic risk. Among them, apo
B : apo A-I has been proposed as the marker with the highest
predictive value for cardiovascular disease.26 Moreover, acromegalic
patients can also present an increment in the proportion of small
and dense LDL particles, given that Mc Laughlin et al.27 have recently
proposed that the above mentioned triglycerides : HDL-C ratio can
be employed as a predictor of insulin resistance and also of the
proportion of this highly atherogenic LDL subpopulation. Arosio
et al.11 have also evaluated the physical properties of LDL by
ultracentrifugation and proved that acromegalic individuals have
smaller and/or denser LDL particles, coincident both with the results
reported by Tan et al.7 and with our conclusions. Matching with the
alterations described in plasma lipoproteins, CETP activity was
found to be higher in patients than in controls. As it has also been
shown by Tan et al.,7 this lipid transfer protein might be partially
responsible for generating small and dense LDL particles. These
results differ from another study that was carried out employing a
different method which evaluates the transfer of cholesteryl esters
form LDL to HDL particles.9
Although insulin resistance itself could be crucial for modifying
the lipoprotein profile, it must be noted that GH has a direct effect
on lipoprotein metabolism.28,29 This relationship could explain the
presence of an altered lipid profile in acromegalic patients in the
absence of insulin resistance. Actually, GH inhibits lipoprotein lipase
from adipose tissue and stimulates hepatic lipase and hormone-
sensitive lipase, the latter being responsible for free fatty acid release
from adipose tissue, which are then taken by the liver and used for
triglyceride synthesis. Accordingly, in the present work, GH, IGF-1
and IGFBP-3 were positively associated with plasma levels of glucose,
insulin, glucose : insulin, HOMA, triglycerides, VLDL-C, and apo B.
In the search of biomarkers which provide an independent
diagnostic or prognostic value of the atherosclerotic process and/or
of its sequels, we evaluated CRP, LpPLA2, endothelin-1, VCAM-1,
white blood cell count and leucocyte cell adhesion molecules. These
factors reflect the underlying biology of the vessel wall, which could
also be influenced by a direct effect of GH and IGF-1. Some authors
have postulated that GH and its tissue effector, IGF-1, would exert
a protective effect on the cardiovascular system.30 Nevertheless, this
hypothesis may be hardly extrapolated to acromegalic patients, as
Fig. 1 Cell adhesion molecule content (CD18, CD49d, CD54) in monocytes 
(Panel A), polymorphonuclear cells (Panel B) and lymphocytes (Panel C) 
from acromegalic patients (n = 18) and control subjects (n = 18) measured 
by flow cytometry. *P < 0·05 vs. acromegalic patients.
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most of those studies have been carried out administering exogenous
GH or IGF-1, thus creating a short-term hormonal excess, in con-
trast to acromegaly which represents an in vivo model with a chronic
increment in GH and IGF-1 levels. Moreover, most of these studies
measured parameters dealing with cardiac contractility and not
biomarkers of endothelial dysfunction.
To our knowledge, this is the first time that higher endothelin-1
levels are reported in acromegalic patients in comparison to healthy
controls. Furthermore, endothelin-1 was positively related to GH,
IGF-1 and IGFBP-3, thus suggesting an association between
endothelin-1 and the extent of acromegaly activity. These are inter-
esting findings given that endothelin-1 has several atherogenic
and/or inflammatory properties such as the regulation of the release
of vasoactive substances and the stimulation of smooth muscle
mitogenesis and cardiac contraction.31 Elevated plasma levels of
endothelin-1 have been associated with coronary artery disease,
essential hypertension and heart failure.32 In acromegalic patients,
endothelin-1 can be increased in response to GH excess, which has
been reported to induce tumour necrosis factor (TNF)-α and
interleukin (IL)-1 secretion by mononuclear blood cells.33 Both
TNF-α and IL-1, together with IGF-1, which is also increased in
acromegaly, are able to regulate endothelin-1 expression.34 This
regulation seems to primarily occur at the level of mRNA, which is
achieved by controlling the activity of the promoter and the stability
of mRNA.35 Our data also evidenced a positive association between
endothelin-1 and VCAM-1, a cell adhesion molecule of endothelial
location that belongs to the immunoglobulin superfamily and that
actively participates in the firm adhesion and extravasation of
circulating leucocytes into the artery wall.36 The observed correlation
is in agreement with the mechanism described by Li et al.37 by which
endothelin-1 seems to directly stimulate arterial VCAM-1 expression
through its receptor-mediated activation of NADPH oxidase and
superoxide formation. Moreover, endothelin-1 also correlated with
lymphocyte CD49d, which was, in turn, significantly higher in
acromegalic patients than in healthy controls. This increment in
lymphocyte CD49d seems to reflect the presence of activated
lymphocytes given that this cell adhesion molecule is part of the
VLA-4 complex, which interacts with endothelial VCAM-1 and,
consequently, mediates leucocyte migration into the intima.36 Then,
lymphocytes in the artery wall trigger the inflammatory process by
producing diverse cytokines, such as interferon γ, which has been
shown to play different roles in mediating foam cell formation,
smooth muscle cell proliferation and regulating the production of
matrix metalloproteinases, thereby influencing plaque stability.38
Among the different CDs evaluated in monocytes, lymphocytes and
polymorphonuclear cells in the present study, only lymphocyte
CD49d varied in relation with acromegaly. Diverse CDs located on
the surface of different cellular types seem to respond to differential
regulatory mechanisms, which have not been fully elucidated up to
date.
Regarding CRP, which has been implicated in multiple aspects of
atherogenesis and plaque vulnerability, similar values were detected
in both groups. Nevertheless, it must be noted that CRP was
positively associated with lymphocyte CD49d, which was increased
in acromegalic patients. Sesmilo et al.14 attributed the lack of higher
CRP levels in acromegalic patients to low-IL-6 concentration, a
decrease that was, in turn, assigned to the decrease in fat proportion.
In this and other studies, CRP was negatively associated with GH,
consistent with a negative regulation of the acute-phase response by
GH.39 The mechanisms underlying this negative association are
unclear, but there is strong evidence of a complex crosstalk between
GH and acute-phase cytokine signalling at the molecular level.40
Other two candidate biomarkers of cardiovascular disease,
LpPLA2 and white blood cell count, failed to evidence any difference
between acromegalic patients and healthy controls. Although
different epidemiological studies have reported that LpPLA2 may be
a predictor of coronary artery disease, the topic is highly controversial.
Some authors postulate that LpPLA2 would only vary in parallel to
variations in LDL levels, whereas others attribute an antioxidant
antiatherogenic capacity to LpPLA2.
41 Increases in white blood cell
count have been fundamentally observed in acute myocardial
infarction, which is known to trigger a systemic response to a
necrotic insult characterized not only by leucocytosis but also by the
synthesis of acute-phase proteins such as CRP.42 In our study, the
synthesis of this protein was not modified in this group of acrome-
galic patients. Further studies are necessary to disclose the precise
factors that regulate these atherogenic biomarkers or risk factors in
acromegaly.
In conclusion, active acromegalic patients presented subtle
modifications in the lipid and lipoprotein profile, higher endothelin-
1 levels and elevated lymphocyte CD49d content, all of which were
independent of BMI. Taken together, the alterations here described
seem to contribute to constituting a state of higher propensity for
the development of atherosclerotic cardiovascular disease, which
adds to the presence of specific cardiomyopathy in acromegaly.
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